198 related articles for article (PubMed ID: 6290115)
21. Bacterial lipopolysaccharide, phorbol myristate acetate, and muramyl dipeptide stimulate the expression of a human monocyte surface antigen, Mo3e.
Todd RF; Alvarez PA; Brott DA; Liu DY
J Immunol; 1985 Dec; 135(6):3869-77. PubMed ID: 3934269
[TBL] [Abstract][Full Text] [Related]
22. Comparative effect of muramyl dipeptide in vivo and in vitro on the tumoricidal activity of rat peritoneal macrophages.
Reisser D; Jeannin JF; Lagadec P; Martin F
J Biol Response Mod; 1985 Oct; 4(5):460-3. PubMed ID: 4078593
[TBL] [Abstract][Full Text] [Related]
23. Enhanced superoxide production by rat alveolar macrophages stimulated in vitro with biological response modifiers.
Badger AM
J Leukoc Biol; 1986 Dec; 40(6):725-36. PubMed ID: 3023513
[TBL] [Abstract][Full Text] [Related]
24. Involvement of reactive oxygen metabolites in the candidacidal activity of human neutrophils stimulated by muramyl dipeptide or tumor necrosis factor.
Jupin C; Parant M; Chedid L
Immunobiology; 1989 Nov; 180(1):68-79. PubMed ID: 2560462
[TBL] [Abstract][Full Text] [Related]
25. Potential adjuvants for synthetic vaccines. I. Modulators of macrophage activation.
Solange A
Chem Phys Lipids; 1995 Jan; 75(1):51-8. PubMed ID: 7697782
[TBL] [Abstract][Full Text] [Related]
26. Polymorphonuclear leukocyte activation by a synthetic muramyl dipeptide analog.
Osada Y; Otani T; Sato M; Une T; Matsumoto K; Ogawa H
Infect Immun; 1982 Dec; 38(3):848-54. PubMed ID: 6295949
[TBL] [Abstract][Full Text] [Related]
27. Activation of mouse peritoneal adherent cells with N-acyl muramyl dipeptide derivatives.
Nishimura K; Okumura H; Saiki I; Okuyama H; Azuma I
Infect Immun; 1985 Mar; 47(3):665-9. PubMed ID: 3882562
[TBL] [Abstract][Full Text] [Related]
28. MDP(Lysyl)GDP, a nontoxic muramyl dipeptide derivative, inhibits cytokine production by activated macrophages and protects mice from phorbol ester- and oxazolone-induced inflammation.
Zunic M; Bahr GM; Mudde GC; Meingassner JG; Lam C
J Invest Dermatol; 1998 Jul; 111(1):77-82. PubMed ID: 9665390
[TBL] [Abstract][Full Text] [Related]
29. Correlation between release of reactive oxygen intermediates and inhibition of Toxoplasma multiplication in mouse peritoneal and alveolar macrophages and kidney cells after in vitro incubation with Obioactin, lonomycin A, muramyl dipeptide, lipopolysaccharide or Toxoplasma lysate antigen.
Saito A; Sakurai H; Saito T; Taji S; Miyagami T; Suzuki N; Seitz HM; Osaki H
Zentralbl Bakteriol Mikrobiol Hyg A; 1987 May; 264(3-4):446-54. PubMed ID: 3660981
[TBL] [Abstract][Full Text] [Related]
30. Muramyl dipeptide mimicry in the regulation of murine macrophage activation by serotonin.
Polanski M; Vermeulen MW; Wu J; Karnovsky ML
Int J Immunopharmacol; 1995 Mar; 17(3):225-32. PubMed ID: 7558518
[TBL] [Abstract][Full Text] [Related]
31. Effect of cisplatin, lipopolysaccharide, muramyl dipeptide and recombinant interferon-gamma on murine macrophages in vitro. II. Production of H2O2, O2- and interleukin-1.
Sodhi A; Geetha B
Nat Immun Cell Growth Regul; 1989; 8(2):108-16. PubMed ID: 2548090
[TBL] [Abstract][Full Text] [Related]
32. Effects of muramyl dipeptide and trehalose dimycolate on resistance of mice to Toxoplasma gondii and Acanthamoeba culbertsoni infections.
Masihi KN; Bhaduri CR; Werner H; Janitschke K; Lange W
Int Arch Allergy Appl Immunol; 1986; 81(2):112-7. PubMed ID: 3759255
[TBL] [Abstract][Full Text] [Related]
33. Comparison of various assays to quantitate macrophage activation by biological response modifiers.
Schultz RM; Nanda S; Altom MG
J Immunopharmacol; 1984; 6(4):257-75. PubMed ID: 6098612
[TBL] [Abstract][Full Text] [Related]
34. Effects of disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP) on interleukin 1 production by macrophages.
Aida Y; Toda Y; Shimakoshi Y; Yamada K; Aono M
Microbiol Immunol; 1986; 30(11):1199-206. PubMed ID: 3027515
[TBL] [Abstract][Full Text] [Related]
35. Differential mRNA responses in human macrophages activated by interferon-gamma and muramyl dipeptide.
Vermeulen MW; David JR; Remold HG
J Immunol; 1987 Jul; 139(1):7-9. PubMed ID: 3108404
[No Abstract] [Full Text] [Related]
36. Effects of muramyl dipeptide treatment on resistance to infection with Toxoplasma gondii in mice.
Krahenbuhl JL; Sharma SD; Ferraresi RW; Remington JS
Infect Immun; 1981 Feb; 31(2):716-22. PubMed ID: 7216470
[TBL] [Abstract][Full Text] [Related]
37. [Role of alveolar macrophages and neutrophils in the defense system against infection of Pseudomonas aeruginosa in the respiratory tract and the effect of derivative of muramyl dipeptide].
Maeda M; Ozaki T; Yasuoka S; Ogura T
Nihon Kyobu Shikkan Gakkai Zasshi; 1990 Jan; 28(1):135-42. PubMed ID: 2355674
[TBL] [Abstract][Full Text] [Related]
38. Effects of reactive oxygen intermediate scavengers on the antitoxoplasmic activity of activated macrophages.
Saito A; Igarashi I; Miyahara K; Venturini C; Claveria FG; Hirose T; Suzuki N; Ono K
Parasitol Res; 1992; 78(1):28-31. PubMed ID: 1584743
[TBL] [Abstract][Full Text] [Related]
39. Effect of muramyl peptides and tumor necrosis factor on oxidative responses of human blood phagocytes.
Jupin C; Parant M; Chedid L
Immunol Lett; 1989 Sep; 22(3):187-92. PubMed ID: 2553589
[TBL] [Abstract][Full Text] [Related]
40. Activation of rat alveolar macrophages by gamma interferon to inhibit Toxoplasma gondii in vitro.
Badger AM; Hutchman JS; Sung CP; Bugelski PJ
J Leukoc Biol; 1987 Nov; 42(5):447-54. PubMed ID: 2824644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
